Milestone Pharmaceuticals (MIST) EBITDA Margin (2021 - 2022)
Milestone Pharmaceuticals (MIST) posted EBITDA Margin of 1002.0% for Q3 2022, down 21209.55% on a QoQ basis from 4.75% in Q2 2021.
Milestone Pharmaceuticals (MIST) EBITDA Margin (2021 - 2022) Analysis & Trends
Milestone Pharmaceuticals' EBITDA Margin history runs 2 years deep, the most recent figure standing at 1002.0% for Q3 2022.
- Quarterly EBITDA Margin changed N/A year-over-year to 1002.0% in Q3 2022, while the trailing twelve-month figure through Sep 2022 was 381.98% (changed N/A YoY) and the FY2021 annual result came in at 287.15%, changed N/A from the prior year.
- EBITDA Margin was 1002.0% for Q3 2022 at Milestone Pharmaceuticals, down from 4.75% in the prior quarter.
- Across five years, EBITDA Margin topped out at 4.75% in Q2 2021 and bottomed at 1002.0% in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Milestone Pharmaceuticals | 156.34 Mn | -27.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -1,002.00% |
| Jun 30, 2021 | 4.75% |